Heart Test Labs Appoints Senior VP of Business Development

Heart Test Laboratories Inc. (HTL) has appointed Brian L. Allen as senior vice president of business development. In this role, Allen will lead the company’s commercial launch of its MyoVista electrocardiographic device. He will be responsible for building the sales team and distribution partners on a global basis. Allen joins the senior executive team and will report directly to CEO Mark Hilz.
 
Allen has more than 20 years of medical device experience that includes a track record of multiple first-to-market medical device innovations by developing strategies and building successful sales teams that achieved successful market adoption. Allen joins Heart Test Laboratories as it is preparing for commercialization after having recently submitted a 510k application to the U.S. Food and Drug Administration and CE Mark technical file for approval. “We are excited to have an executive of Brian’s caliber and experience leading our commercialization efforts. Brian brings to Heart Test Laboratories a strong track record of developing and executing multiple successful commercialization efforts in the medical device market,” said Hilz.
 
Recently, Allen served as vice president of Ssles and commercial marketing for OrthoSensor Inc., where he led the planning and successful launch of their global sales and market expansion through distribution partners. Prior to that, he led the company’s domestic sales strategy, and was responsible for launch which included sales, marketing and market education of VERASENSE, the orthopedic industry’s first sensor-assisted technology used in total knee replacement surgery.
 
Before joining OrthoSensor, Allen served as director of sales and marketing for MAKO Surgical Corp. responsible for planning and executing the commercial market launch and sustainable growth of the orthopedic industry’s first robotic-assisted surgery system and implants. MAKO Surgical Corp. was acquired by Stryker Corp. for $1.65 billion in 2013.
 
Early in his career, Allen held various progressive sales and leadership roles at Medtronic Neurological and Coronary Vascular business units, Zimmer Holdings Inc., and Burrows Inc., which subsequently was acquired by Owens and Minor Inc.
 
“Meaningful innovation that has the potential to improve clinical care, reduce care-pathway costs and significantly enhance and extend the quality of life of patients, inspires and excites me. MyoVista is poised to transform the early detection of heart disease and establish a new benchmark for heart disease screening,” said Allen.
 
The search was conducted for Heart Test Labs by Paula Rutledge of Legacy MedSearch.
 
HTL develops medical devices using patented proprietary technology that focus on the early detection of heart disease. MyoVista’s technology facilitates the early identification of ischemic and other heart myocardial dysfunctions, which can enable improved screening for coronary arterial disease and other cardiac abnormalities. MyoVista uses standard 12-lead resting ECG protocols to provide a traditional ECG incorporating interpretive analysis, as well as further proprietary informatics to assist a physician in identifying the presence of heart disease. MyoVista is ideally suited for use in both primary care and hospital environments, and has a 15.6-inch high-resolution touchscreen and incorporates many user features and functionality commonly associated with a tablet device, which makes it intuitive and easy to use, thereby reducing training time.
 
Heart Disease kills 7 million people worldwide each year, more than all cancers combined, and is the largest spend area in healthcare. MyoVista helps to bridge the “diagnostic gap” in heart disease today, which is the identification of patients prior to an adverse cardiac event, such as a heart attack.
 
Heart Test Laboratories is a privately held U.S. corporation in Westlake, Texas, which to date has been funded by private investors.